Doses administered used for reporting rate calculations have been adjusted to account for the delay between vaccination and reporting. The information on this page reflects detailed case information data from the Public Health Agency of Canada’s Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) and Health Canada’s Canada Vigilance program.Learn more about reporting adverse events. If you experience an adverse event following immunization with a COVID-19 vaccine in Canada, please contact your healthcare provider. Of these, 947 were following a bivalent vaccine, of which 692 were considered non-serious (0.007% of bivalent COVID-19 doses administered) and 255 (0.003% of bivalent COVID-19 doses administered) were considered serious.A total of 99,034,764 vaccine doses have been administered in Canada as of September 15, 2023, including 9,611,886 bivalent doses.Of the individual reports ( of all doses administered), were considered serious ( of all doses administered).We’ll respond to any safety issues right away and will inform Canadians about any risks that arise in Canada. Health Canada, the Public Health Agency of Canada (PHAC), the provinces and territories, and manufacturers continue to closely monitor the safety of COVID-19 vaccines.Evidence indicates that the benefits of COVID-19 vaccines continue to outweigh the risks of the disease.Health Canada and PHAC continue to monitor this closely. In Canada as well, we’ve detected no safety signal of ischemic stroke following COVID-19 mRNA bivalent boosters. As of April 19, 2023, FDA’s monitoring systems and programs have not detected any safety signals for ischemic stroke following COVID-19 mRNA bivalent boosters.No new safety signals have been identified during this reporting period.Total adverse event following immunization reports that were serious
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |